AstraZeneca announced a $2 billion U.S. investment to expand biologics manufacturing in Maryland, nearly doubling commercial capacity at its Frederick site and building a new clinical‑supply facility in Gaithersburg. The expansion will support commercial production and clinical supply for the company’s rare disease portfolio and is expected to create hundreds of skilled jobs. The company said both sites will integrate automation, AI and data analytics and adhere to high environmental standards, with operations expected by 2029. AstraZeneca framed the move as strengthening U.S. supply resilience and accelerating access to transformative therapies. The commitment underscores continued onshoring and capacity expansion by major pharmas amid supply‑chain concerns and signals opportunities for local bioprocess suppliers and workforce development.